Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cem Demirkiran

Showing results (1-10 of 34) with videos related to

Pageof 4
Sort By:
Urogynecology (Philadelphia, Pa.)|March 19, 2025
Activity Restrictions After Midurethral Sling: A Randomized Controlled TrialPedro Alvarez, Cem Demirkiran, Leslie Rickey, et al.
Clinical Imaging|January 24, 2021
Effects of iron oxide particles on MRI and mammography in breast cancer patients after a sentinel lymph node biopsy with paramagnetic tracersErkin Aribal, Levent Çelik, Cem Yilmaz, et al.
Cureus|November 19, 2025
Successful Sequential Use of the Antibody-Drug Conjugate Trastuzumab Deruxtecan After Progression on Sacituzumab Govitecan in a Recurrent Treatment-Resistant Ovarian Cancer Patient: A Case ReportVictoria M Ettorre, Michelle Greenman, Luca Palmieri, et al.
Gynecologic Oncology Reports|June 16, 2023
Pembrolizumab and lenvatinib in recurrent ovarian clear cell carcinoma resistant to chemotherapyBlair McNamara, Stefania Bellone, Cem Demirkiran, et al.
Gynecologic Oncology Reports|August 7, 2024
Sacituzumab govitecan in heavily pretreated, platinum-resistant high grade serous ovarian cancerMichelle Greenman, Stefania Bellone, Cem Demirkiran, et al.
Gynecologic Oncology Reports|June 16, 2023
Trastuzumab deruxtecan in recurrent uterine serous carcinoma resistant to trastuzmab based-chemotherapyBlair McNamara, Stefania Bellone, Cem Demirkiran, et al.
Journal of Obstetrics and Gynaecology : the Journal of the Institute of Obstetrics and Gynaecology|October 13, 2020
Perioperative, postoperative and anatomical outcomes of robotic sacrocolpopexyGokhan Sami Kilic, Toy Lee, Kelsey Lewis, et al.
International Journal of Molecular Sciences|February 10, 2024
Mitochondrial Unfolded Protein Response Gene <i>Clpp</i> Is Required for Oocyte Function and Female FertilityYagmur Ergun, Aysegul Gizem Imamoglu, Mauro Cozzolino, et al.
Gynecologic Oncology Reports|June 29, 2026
Activity of datopotamab deruxtecan in TROP2-expressing low-grade serous ovarian cancer: a preclinical studySarah Ottum, Orazio De Tommasi, Cem Demirkiran, et al.
Gynecologic Oncology|September 4, 2025
Effective preclinical activity of datopotamab deruxtecan (Dato-DXd), an ADC targeting trophoblast cell-surface antigen 2 (TROP2), against primary cervical carcinoma cell lines and xenograftsVictoria M Ettorre, Cem Demirkiran, Stefania Bellone, et al.
Pageof 4

Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
Urogynecology (Philadelphia, Pa.)|March 19, 2025
Activity Restrictions After Midurethral Sling: A Randomized Controlled TrialPedro Alvarez, Cem Demirkiran, Leslie Rickey, et al.
Clinical Imaging|January 24, 2021
Effects of iron oxide particles on MRI and mammography in breast cancer patients after a sentinel lymph node biopsy with paramagnetic tracersErkin Aribal, Levent Çelik, Cem Yilmaz, et al.
Cureus|November 19, 2025
Successful Sequential Use of the Antibody-Drug Conjugate Trastuzumab Deruxtecan After Progression on Sacituzumab Govitecan in a Recurrent Treatment-Resistant Ovarian Cancer Patient: A Case ReportVictoria M Ettorre, Michelle Greenman, Luca Palmieri, et al.
Gynecologic Oncology Reports|June 16, 2023
Pembrolizumab and lenvatinib in recurrent ovarian clear cell carcinoma resistant to chemotherapyBlair McNamara, Stefania Bellone, Cem Demirkiran, et al.
Gynecologic Oncology Reports|August 7, 2024
Sacituzumab govitecan in heavily pretreated, platinum-resistant high grade serous ovarian cancerMichelle Greenman, Stefania Bellone, Cem Demirkiran, et al.
Gynecologic Oncology Reports|June 16, 2023
Trastuzumab deruxtecan in recurrent uterine serous carcinoma resistant to trastuzmab based-chemotherapyBlair McNamara, Stefania Bellone, Cem Demirkiran, et al.
Journal of Obstetrics and Gynaecology : the Journal of the Institute of Obstetrics and Gynaecology|October 13, 2020
Perioperative, postoperative and anatomical outcomes of robotic sacrocolpopexyGokhan Sami Kilic, Toy Lee, Kelsey Lewis, et al.
International Journal of Molecular Sciences|February 10, 2024
Mitochondrial Unfolded Protein Response Gene <i>Clpp</i> Is Required for Oocyte Function and Female FertilityYagmur Ergun, Aysegul Gizem Imamoglu, Mauro Cozzolino, et al.
Gynecologic Oncology Reports|June 29, 2026
Activity of datopotamab deruxtecan in TROP2-expressing low-grade serous ovarian cancer: a preclinical studySarah Ottum, Orazio De Tommasi, Cem Demirkiran, et al.
Gynecologic Oncology|September 4, 2025
Effective preclinical activity of datopotamab deruxtecan (Dato-DXd), an ADC targeting trophoblast cell-surface antigen 2 (TROP2), against primary cervical carcinoma cell lines and xenograftsVictoria M Ettorre, Cem Demirkiran, Stefania Bellone, et al.
Pageof 4